The estimated Net Worth of Timothy Coughlin is at least 4.68 百万$ dollars as of 30 May 2024. Mr. Coughlin owns over 50,000 units of Retrophin stock worth over 3,920$ and over the last 18 years he sold RTRX stock worth over 4,423,810$. In addition, he makes 255,650$ as Independent Director at Retrophin.
Sign up
Mr. Coughlin RTRX stock SEC Form 4 insiders trading
Timothy has made over 31 trades of the Retrophin stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of RTRX stock worth 87,500$ on 30 May 2024.
The largest trade he's ever made was selling 70,000 units of Retrophin stock on 7 January 2014 worth over 1,172,500$. On average, Timothy trades about 7,143 units every 56 days since 2007. As of 30 May 2024 he still owns at least 56,000 units of Retrophin stock.
You can see the complete history of Mr. Coughlin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Timothy Coughlin biography
Timothy P. Coughlin, CPA is an Independent Director of Company. Mr. Coughlin is the former Chief Financial Officer of Neurocrine Biosciences, Inc. ("Neurocrine"), a biopharmaceutical company that has received FDA approval for INGREZZA® (valbenazine) and ORILISSA® (elagolix), both of which were discovered and developed during his tenure at Neurocrine from 2002 to 2018. Mr. Coughlin serves on the board of directors of Fate Therapeutics, Inc., and Tyr Pharma, Inc., both biotechnology companies, and also served on the board of directors of Peloton Therapeutics, Inc. prior to its sale to Merck in 2019. Prior to joining Neurocrine, he was with Catholic Health Initiatives, a nationwide integrated healthcare delivery system, where he served as Vice President, Financial Services. Mr. Coughlin also served as a Senior Manager in the Health Sciences practice of Ernst & Young LLP and its predecessors from 1989 to 1999. Mr. Coughlin holds a master's degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University. Mr. Coughlin is a certified public accountant in both California and Pennsylvania.
What is the salary of Timothy Coughlin?
As the Independent Director of Retrophin, the total compensation of Timothy Coughlin at Retrophin is 255,650$. There are 9 executives at Retrophin getting paid more, with Eric Dube having the highest compensation of 9,679,320$.
How old is Timothy Coughlin?
Timothy Coughlin is 53, he's been the Independent Director of Retrophin since 2015. There are 8 older and 3 younger executives at Retrophin. The oldest executive at Retrophin, Inc. is Gary Lyons, 68, who is the Independent Chairman of the Board.
What's Timothy Coughlin's mailing address?
Timothy's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC.;, 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131.
Insiders trading at Retrophin
Over the last 12 years, insiders at Retrophin have traded over 26,547,782$ worth of Retrophin stock and bought 585,006 units worth 5,991,663$ . The most active insiders traders include Martin Shkreli、Ron Squarer、Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of 1,651$. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth 174,675$.
What does Retrophin do?
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
What does Retrophin's logo look like?
Complete history of Mr. Coughlin stock trades at Atyr Pharma Inc、Fate Therapeutics Inc、Neurocrine Biosciences、Retrophin
Retrophin executives and stock owners
Retrophin executives and other stock owners filed with the SEC include:
-
Eric Dube,
President, Chief Executive Officer, Director -
Elizabeth Reed,
Senior Vice President, General Counsel and Corporate Secretary -
Noah Rosenberg,
Chief Medical Officer -
Peter Heerma,
Chief Commercial Officer -
William Rote,
Senior Vice President and Head of Research and Development -
Laura Clague,
Chief Financial Officer, Senior Vice President -
Stephen Aselage,
Director -
Sandra Poole,
Independent Director -
Gary Lyons,
Independent Chairman of the Board -
Timothy Coughlin,
Independent Director -
Jeffrey Meckler,
Independent Director -
John Orwin,
Independent Director -
Roy Baynes,
Independent Director -
Ron Squarer,
Independent Director -
Suzanne Bruhn,
Independent Director -
Neil F. Mc Farlane,
Chief Operating Officer -
Jensen Margaret E Valeur,
General Counsel -
John W Kozarich,
Director -
Alvin Shih,
EVP of Research & Development -
Cornelius E Golding,
Director -
Steve Aselage,
Director -
Martin Shkreli,
Chief Executive Officer -
Steven Gary Richardson,
Director -
Horacio Plotkin,
Chief Medical Officer -
Jeffrey Paley,
Director -
Marc L Panoff,
Chief Financial Officer